JP2018507234A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507234A5
JP2018507234A5 JP2017546185A JP2017546185A JP2018507234A5 JP 2018507234 A5 JP2018507234 A5 JP 2018507234A5 JP 2017546185 A JP2017546185 A JP 2017546185A JP 2017546185 A JP2017546185 A JP 2017546185A JP 2018507234 A5 JP2018507234 A5 JP 2018507234A5
Authority
JP
Japan
Prior art keywords
thiazol
phenyl
trifluoromethanesulfonamide
chloro
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017546185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020644 external-priority patent/WO2016141159A1/en
Publication of JP2018507234A publication Critical patent/JP2018507234A/ja
Publication of JP2018507234A5 publication Critical patent/JP2018507234A5/ja
Withdrawn legal-status Critical Current

Links

JP2017546185A 2015-03-04 2016-03-03 肝臓線維症、コレステロールの上昇およびインスリン抵抗性を処置する際における使用のためのsrebp遮断薬 Withdrawn JP2018507234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128251P 2015-03-04 2015-03-04
US62/128,251 2015-03-04
PCT/US2016/020644 WO2016141159A1 (en) 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance

Publications (2)

Publication Number Publication Date
JP2018507234A JP2018507234A (ja) 2018-03-15
JP2018507234A5 true JP2018507234A5 (https=) 2019-04-18

Family

ID=55754401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546185A Withdrawn JP2018507234A (ja) 2015-03-04 2016-03-03 肝臓線維症、コレステロールの上昇およびインスリン抵抗性を処置する際における使用のためのsrebp遮断薬

Country Status (5)

Country Link
US (1) US10183015B2 (https=)
EP (1) EP3265088A1 (https=)
JP (1) JP2018507234A (https=)
CA (1) CA2978627A1 (https=)
WO (1) WO2016141159A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105491A1 (en) 2014-12-23 2016-06-30 Fgh Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
JP2018507235A (ja) 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー ステロール調節エレメント結合タンパク質(srebp)阻害剤
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
JP7071981B2 (ja) 2016-09-07 2022-05-19 エフジーエイチ バイオテック,インコーポレーテッド 疾患の治療のための二置換ピラゾール化合物
AU2019212959A1 (en) * 2018-01-29 2020-09-17 Capulus Therapeutics, Llc SREBP inhibitors comprising a 6-membered central ring
EP3917513A4 (en) * 2019-01-28 2022-11-09 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A THIOPHENE CENTER RING
WO2020191163A1 (en) * 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
CN114945365A (zh) * 2019-11-13 2022-08-26 卡普勒斯疗法有限责任公司 包括噻吩中心环的srebp抑制剂
TW202128676A (zh) * 2019-11-13 2021-08-01 美商卡普勒斯療法有限責任公司 具有環醯胺的噻吩化合物及其用途
WO2021154735A1 (en) * 2020-01-27 2021-08-05 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
EP4185584A1 (en) * 2020-07-24 2023-05-31 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
NZ506507A (en) 1998-02-09 2003-08-29 Dimensional Pharm Inc Heteroaryl amidine, methylamidine or guanidine derivatives useful as urokinase inhibitors
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DE60022386T2 (de) 1999-12-16 2006-06-22 Schering Corp. Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
TWI275589B (en) 2000-06-22 2007-03-11 Dow Agrosciences Llc 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006135648A2 (en) 2005-06-09 2006-12-21 Schering-Plough Ltd. Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
JP5261176B2 (ja) 2005-08-16 2013-08-14 アイカジェン, インコーポレイテッド 電位作動型ナトリウムチャンネル阻害剤
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
EP2120580B1 (en) 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
AU2008340113B2 (en) 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2011085269A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
JP2014062047A (ja) 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd ピラゾール誘導体
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
WO2013096630A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20140364460A1 (en) 2012-01-18 2014-12-11 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
EP3013371A4 (en) * 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
SG10201806370QA (en) * 2013-08-28 2018-08-30 Medivation Tech Llc Heterocyclic compounds and methods of use
JP2018507235A (ja) 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー ステロール調節エレメント結合タンパク質(srebp)阻害剤

Similar Documents

Publication Publication Date Title
JP2018507234A5 (https=)
RU2016111138A (ru) Гетероциклические соединения и способы их применения
RU2018138707A (ru) Замещенные гетероарилом пиридины и способы применения
RU2392275C2 (ru) Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
JP5261383B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
AU2007265455B2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
JP2010533158A5 (https=)
JP2020516671A5 (https=)
JP2014513122A5 (https=)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2007523142A5 (https=)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2009542659A5 (https=)
JP2009529059A5 (https=)
JP2019537594A5 (https=)
RU2014152625A (ru) Конденсированные с гетероарилкетонами азадекалины - модуляторы глюкокортикоидных рецепторов
JP2015517580A5 (https=)
JP2009534386A5 (https=)
JP2018507235A5 (https=)
JP2015509510A5 (https=)
JP2019516737A5 (https=)
JP2013517279A5 (https=)
JP2009504791A5 (https=)
JP2019529445A5 (https=)
RU2019122999A (ru) Новое соединение и его фармакологически приемлемая соль